dabigatran has been researched along with Idiopathic Parkinson Disease in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Grammas, P; Iannucci, J; Johnson, SL; Seeram, NP | 1 |
Abd El Fattah, MA; Ahmed, LA; El-Sayeh, BM; Kandil, EA; Sayed, RH | 1 |
2 other study(ies) available for dabigatran and Idiopathic Parkinson Disease
Article | Year |
---|---|
Inhibiting thrombin improves motor function and decreases oxidative stress in the LRRK2 transgenic Drosophila melanogaster model of Parkinson's disease.
Topics: Animals; Animals, Genetically Modified; Antithrombins; Dabigatran; Disease Models, Animal; Drosophila melanogaster; Female; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Locomotion; Male; Mutation; Oxidative Stress; Parkinson Disease; Thrombin | 2020 |
Modulatory Role of Nurr1 Activation and Thrombin Inhibition in the Neuroprotective Effects of Dabigatran Etexilate in Rotenone-Induced Parkinson's Disease in Rats.
Topics: alpha-Synuclein; Animals; Dabigatran; Dopamine; Dopaminergic Neurons; Inflammation; Male; Neostriatum; Neuroprotective Agents; Nuclear Receptor Subfamily 4, Group A, Member 2; Parkinson Disease; Rats, Wistar; Rotenone; Substantia Nigra; Thrombin | 2018 |